Q2 saw the $590M sale of the Feed Ingredient business, with remaining operations focusing on human health and nutrition. Revenue grew 6% to $94M, EBITDA rose 35%, and an extraordinary dividend is planned post-transaction. Human Health Ingredient and international channels showed strong growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.